Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04191928 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
A Phase 1 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04191928 is a Phase 1 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 4 participants.
The verdict
NCT04191928, a Phase 1 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Study investigators will examine the absorption characteristics of apixaban, a direct-acting oral anticoagulation, in patients who have underwent a particular kind of surgery (pancreaticoduodenectomy) which involves resection of the duodenum.
Interventions
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-03-03 |
| Est. Completion | 2021-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04191928
The ClinicalTrials.gov registry entry for NCT04191928 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apixaban is the first listed.
NCT04191928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04191928 about?
NCT04191928 is a clinical study titled "Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy". Study investigators will examine the absorption characteristics of apixaban, a direct-acting oral anticoagulation, in patients who have underwent a particular kind of surgery (pancreaticoduodenectomy) which involves resection of the duodenum.
What is the current status of trial NCT04191928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-03-03. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT04191928?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT04191928?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.